Targeting Lewy Bodies Specific Pathology Using Biomarkers
|Male and Female Patients
|Helen Mejia-Santana: 212-305-9183 / email@example.com
The aim of this study is to develop better biomarkers for the diagnosis and treatment of Lewy Body disorders. In particular, there is a need to understand how the contribution of coexisting Alzheimer's disease may affect the diagnosis and clinical course of Lewy Body disorders. This study will recruit a group of individuals with Lewy Body disorders causing cognitive impairment or dementia. Participants will have up to 4-5 visits over 3.5 years. Participants will have a comprehensive neurological evaluation, cognitive and behavior tests, and will donate blood, urine, and cerebrospinal fluid samples.
Karen Marder, MD, MPH
|Have you been diagnosed with dementia with Lewy bodies (DLB) or Parkinson's disease with cognitive changes?
|Do you speak English or Spanish?
|Are you able to provide consent to participate in the study at the first visit?
|Are you 18 or older?